Physicians' Academy for Cardiovascular Education

ACS

Neutral outcomes for early intervention strategy compared to standard strategy in NSTEMI patients

3' education - Aug. 28, 2018 - Prof. Thomas Engstrom, Copenhagen, Denmark

P2Y12 inhibitor monotherapy for 23 months after 1 month of DAPT, compared to traditional 12-month DAPT

3' education - Aug. 27, 2018 - Prof. Patrick Serruys, Rotterdam, The Netherlands

Treatment with statin before PCI intervention reduces MACE in patients with ACS

3' education - Mar. 11, 2018 - ACC 2018, Orlando, FL, VS - Otavio Berwanger - São Paulo, Brasil

Results ODYSSEY OUTCOMES study can change clinical practice for treatment of high-risk ACS patients

3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Dr. Valentin Fuster, New York, NY, USA

Treatment of patients on oral anticoagulation who present with ACS

10' education - Sep. 15, 2017 - Dr. Jur ten Berg - Cardiologist, Nieuwegein, The Netherlands
##SCROLLER_ITEMS_FULL_TITLE##

Customising therapy approach in ACS based on underlying pathology seems promising

3' education - Oct. 21, 2016 - ESC - 2016 Rome - Ik-Kyung Jang, MD - Massachusetts General Hospital, Boston, MA, USA

No added value of monitoring platelet function after ACS

3' education - Oct. 6, 2016 - ESC - 2016 Rome - Stefan Gielen, MD - University of Leipzig, Germany
##SCROLLER_ITEMS_FULL_TITLE##

No indication for difference in efficacy between potent platelet inhibitors after PCI

3' education - Aug. 30, 2016 - ESC - 2016 Rome - Steen Dalby Kristensen, MD - Aarhus University, Denmark

Novel strategies targeting residual risk: The promise of PCSK9 inhibiting therapies

10' education - Aug. 28, 2016 - ESC 2016, Rome - Erik Stroes, MD – Academic Medical Center, Amsterdam, The Netherlands - PACE-CME symposium held at ESC 2016 in Rome

Evolving hypotheses on the mechanisms underlying ACS

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Peter Libby, MD - Boston, MA, USA

Changing views on mechanisms of atherosclerosis

10' education - Feb. 12, 2016 - Boston, MA, USA - Prof. Peter Libby (Boston, MA, USA)

C-Reactive Protein, Inflammation and Atherosclerosis

Jan. 24, 2016
##SCROLLER_ITEMS_FULL_TITLE##

Inflammation as target for therapy in atherothrombosis

10' education - Aug. 31, 2015 - ESC London - Prof Paul M Ridker
##SCROLLER_ITEMS_FULL_TITLE##

Inflammation and Thrombosis

10' education - Sep. 29, 2015
##SCROLLER_ITEMS_FULL_TITLE##

The changing character of atherosclerotic disease

3' education - May 24, 2015 - ISA2015, Amsterdam - Prof. Peter Libby

Cardiovascular Inflammation and Immunity in Atherosclerosis:

10' education - June 7, 2015 - Amsterdam
##SCROLLER_ITEMS_FULL_TITLE##

HDL mimetics: New promise in ACS?

3' education - Sep. 15, 2014 - Barcelona 2014 - Prof Kausik Ray MD
##SCROLLER_ITEMS_FULL_TITLE##

New registries on ACS/PCI: how does the real world look like

10' education - Sep. 2, 2014 - Barcelona, ESC - Peter Sinnaeve, MD UZ Leuven
##SCROLLER_ITEMS_FULL_TITLE##

Latest guidelines on ACS/PCI: what are the key changes?

10' education - Sep. 2, 2014 - Barcelona, ESC - Prof. Petr Widimsky, Prague, Czech Republic
##SCROLLER_ITEMS_FULL_TITLE##

ACS/PCI :Patient cases based on real world data

10' education - Sep. 2, 2014 - Barcelona, ESC - Peter Sinnaeve, MD UZ Leuven
##SCROLLER_ITEMS_FULL_TITLE##

ACS/PCI: Patient cases based on latest guidelines

10' education - Sep. 1, 2014 - Barcelona, ESC - Professor Petr Widimský

Statin-loaded HDL nanoparticles

10' education - Jan. 23, 2014 - Raphaël Duivenvoorden - Raphaël Duivenvoorden

Summary | Changing focus in diabetes: From glucose to CV risk management

Munich, Berlin - August 27, 2018

This is a summary of the presentation by prof. Stephan Jacob, in which he talked about the management of diabetes, focusing on the shift from glucose to CV risk management in patients with diabetes.

Summary | SGLT2 inhibition in cardiology: What is the profile of benefit?

Munich, Berlin - August 27, 2018

This is a summary of the presentation by prof. Nikolaus Marx, in which he addressed the mode of action of SGLT2 inhibitors, and presented clinical outcome data and potential mechanisms.

PCSK9-targeted siRNA therapy: effective, safe and durable lipid-lowering irrespective of diabetes status

Literature - Dec. 11, 2018 - Leiter LA et al. - Diabetes Care 2018
A post-hoc analysis showed reduced LDL-c levels and improved lipid profiles up to 180 days with one or two doses of inclisiran on top of standard care in the presence and absence of diabetes, compared to placebo.

A post-hoc analysis showed reduced LDL-c levels and improved lipid profiles up to 180 days with one or two doses of inclisiran on top of standard care in the presence and absence of diabetes, compared to placebo.

Type of existing CVD at baseline affects CV benefits of SGLT2 inhibition

Literature - Dec. 10, 2018 - Zelniker TA et al. - The Lancet 2018
A meta-analysis of three CVOTs showed moderate benefits of SGLT2i on atherosclerotic MACE only in those with ASCVD, whereas robust benefits on HHF and renal disease were observed regardless of baseline CVD or HF.

A meta-analysis of three CVOTs showed moderate benefits of SGLT2i on atherosclerotic MACE only in those with ASCVD, whereas robust benefits on HHF and renal disease were observed regardless of baseline CVD or HF.

Sudden death is the most common cause of death after 30 days post-NSTE-ACS

Literature - Nov. 28, 2018 - Berg DD et al. - Eur Heart J 2018
In a population derived from 14 TIMI clinical trials, CV events caused the majority of deaths post-NSTE-ACS, with recurrent MI representing the most common cause of death within the first 30 days, and sudden death after the first 30 days.

In a population derived from 14 TIMI clinical trials, CV events caused the majority of deaths post-NSTE-ACS, with recurrent MI representing the most common cause of death within the first 30 days, and sudden death after the first 30 days.

Reduction of CV risk with CETP inhibition may be due to a specific reduction of small VLDL

Literature - Nov. 26, 2018 - Blauw LL et al. - Eur J Hum Genet 2018

A Mendelian randomization study combined with metabolic biomarker analysis shows that CETP is an important causal determinant of HDL and VLDL concentration and composition.

GLP-1RA demonstrates CV safety and reduction in secondary mortality outcomes in T2DM

News - Nov. 26, 2018

The phase 3a PIONEER 6 trial met its primary endpoint, showing non-inferiority with regard to MACE, which was driven by a significant reduction in CV and all-cause mortality, compared to placebo, on top of standard care in T2DM.

DPP-4 inhibitor non-inferior to placebo in preventing CV outcomes

Literature - Nov. 21, 2018 - Rosenstock J et al. - J Am Med Assoc 2018

In diabetic patients at high cardio-renal risk, linagliptin was non-inferior to placebo in preventing CV outcomes, but led to slightly more renal outcomes compared with placebo.

Possibly greater reduction in MACE after patient selection for extended DAPT

News - Nov. 19, 2018

AHA 2018 In PEGASUS-TIMI 54, a patient selection strategy identified a subgroup of patients who may benefit more from long-term treatment with ticagrelor and aspirin, with lower bleeding risk.

Antihypertensive treatment does not result in reduced mortality or CV events in low-risk patients with mild hypertension

Literature - Nov. 9, 2018 - Sheppard JP et al. - JAMA Intern Med 2018

In an observational study, antihypertensive treatment was not associated with reduced mortality or rates of CVD in low-risk patients with mild hypertension.

Reduced risk of MACE with PCSK9 inhibitor in patients with ACS

News - Nov. 9, 2018

The ODYSSEY OUTCOMES trial met its primary safety endpoint, showing reduced risk of MACE with alirocumab in patients with ACS compared to placebo, which is dependent on baseline LDL-c levels.

Novel exercise parameter inversely associated with risk of HF and mortality

Literature - Nov. 5, 2018 - Al Rifai M et al. - Heart 2018

In a large cohort study, pulse pressure stress index (P2SI) was inversely associated with risk of HF and all-cause mortality in individuals with suspected CAD.